BioSpace News Archive

Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, pursuant to its existing shelf registration statement.

Rockwell Medical, Inc. (Nasdaq: RMTI), today provided an update on its recent capital raise and a clinical update on safety enhancements to its planned Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC) in home infusion patients.

Coherus BioSciences, Inc., announced that effective June 16, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 409,000 shares of the common stock of the Company to 16 newly hired employees with a per share exercise price of $5.86, the closing trading price on the grant date.

Summit Therapeutics Inc. announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, par value $0.01 as of the close of the market on July 5, 2022.

Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2022, ended March 31, 2022.

uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that the Company granted equity awards to 22 employees as a material inducement to commencing their employment.

CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced the voting results of the Company’s annual general meeting.

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or the “Company”) today announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before shareholders for consideration and approval as set out in the Company’s management information circular dated May 13, 2022 were approved by the requisite majority of votes cast at the meeting.

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has included FLUAD® QUADRIVALENT as a preferentially recommended seasonal influenza vaccine for adults 65 years of age and older.

Applied Therapeutics, Inc. announced the pricing of its underwritten public offering of 20.0 million shares of its common stock, par value $0.0001 per share, 10.0 million pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase up to 30.0 million shares of its common stock.